Summary of Study ST001680

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001079. The data can be accessed directly via it's Project DOI: 10.21228/M8797T This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001680
Study TitleMetabolome of NAFLD in high fat diet mouse model
Study SummaryWe investigated the effects of a RAR beta 2 agonist, AC261066, on the hepatic metabolites changed in high fat fed NAFLD mouse model. We suggest that AC261066 has potential therapeutic relevance for the prevention/treatment of NAFLD and NASH.
Institute
Weill Cornell Medicine
Last NameGudas
First NameLorraine
Address1300 York Ave
Emailchl2029@med.cornell.edu
Phone646-3094389
Submit Date2021-01-27
Raw Data AvailableYes
Raw Data File Type(s)d
Analysis Type DetailLC-MS
Release Date2022-01-27
Release Version1
Lorraine Gudas Lorraine Gudas
https://dx.doi.org/10.21228/M8797T
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR001079
Project DOI:doi: 10.21228/M8797T
Project Title:Metabolome of NAFLD in high fat diet mouse model
Project Summary:We investigated the effects of a RAR beta 2 agonist, AC261066, on the hepatic metabolites changed in high fat fed NAFLD mouse model. We suggest that AC261066 has potential therapeutic relevance for the prevention/treatment of NAFLD and NASH.
Institute:Weill Cornell Medical College
Laboratory:Lorraine Gudas
Last Name:Lorraine
First Name:Gudas
Address:1300 York Ave, New York, NY, 10065, USA
Email:chl2029@med.cornell.edu
Phone:646-3094389

Subject:

Subject ID:SU001757
Subject Type:Mammal
Subject Species:Mus musculus
Taxonomy ID:10090

Factors:

Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)

mb_sample_id local_sample_id Treatment
SA154567anp-neg-Control-217chow
SA154568C18-neg-Control-217bchow
SA154569C18-neg-Control-316bchow
SA154570anp-pos-Control-417bchow
SA154571C18-neg-Control-316chow
SA154572anp-pos-Control-317bchow
SA154573anp-pos-Control-316chow
SA154574anp-pos-Control-316bchow
SA154575anp-pos-Control-317chow
SA154576C18-neg-Control-317chow
SA154577anp-pos-Control-417chow
SA154578C18-neg-Control-417chow
SA154579C18-pos-Control-317chow
SA154580C18-pos-Control-317bchow
SA154581C18-pos-Control-417chow
SA154582C18-pos-Control-417bchow
SA154583C18-pos-Control-316bchow
SA154584C18-pos-Control-316chow
SA154585anp-pos-Control-217bchow
SA154586C18-neg-Control-417bchow
SA154587C18-pos-Control-217chow
SA154588C18-pos-Control-217bchow
SA154589C18-neg-Control-317bchow
SA154590C18-neg-Control-217chow
SA154591anp-neg-Control-317chow
SA154592anp-neg-Control-316bchow
SA154593anp-neg-Control-417chow
SA154594anp-neg-Control-417bchow
SA154595anp-pos-Control-217chow
SA154596anp-neg-Control-316chow
SA154597anp-neg-Control-317bchow
SA154598anp-neg-Control-217bchow
SA154599C18-neg-HFD-316high fat diet
SA154600C18-neg-HFD-416high fat diet
SA154601C18-neg-HFD-417high fat diet
SA154602C18-neg-HFD-217bhigh fat diet
SA154603C18-neg-HFD-217high fat diet
SA154604anp-neg-HFD-316high fat diet
SA154605anp-neg-HFD-217bhigh fat diet
SA154606C18-neg-HFD-216high fat diet
SA154607C18-neg-HFD-4217high fat diet
SA154608anp-neg-HFD-217high fat diet
SA154609C18-pos-HFD-317high fat diet
SA154610C18-pos-HFD-316high fat diet
SA154611C18-pos-HFD-216high fat diet
SA154612C18-pos-HFD-217high fat diet
SA154613C18-pos-HFD-416high fat diet
SA154614anp-neg-HFD-317high fat diet
SA154615anp-neg-HFD-216high fat diet
SA154616C18-pos-HFD-4217high fat diet
SA154617C18-pos-HFD-417high fat diet
SA154618C18-pos-HFD-217bhigh fat diet
SA154619C18-neg-HFD-317high fat diet
SA154620anp-pos-HFD-317high fat diet
SA154621anp-pos-HFD-416high fat diet
SA154622anp-pos-HFD-417high fat diet
SA154623anp-pos-HFD-316high fat diet
SA154624anp-pos-HFD-217bhigh fat diet
SA154625anp-pos-HFD-216high fat diet
SA154626anp-pos-HFD-217high fat diet
SA154627anp-neg-HFD-416high fat diet
SA154628anp-pos-HFD-4217high fat diet
SA154629anp-neg-HFD-417high fat diet
SA154630anp-neg-HFD-4217high fat diet
SA154631anp-pos-HFD-Drug-116high fat diet+AC261066
SA154632anp-neg-HFD-Drug-116high fat diet+AC261066
SA154633C18-pos-HFD-Drug-116high fat diet+AC261066
SA154634C18-neg-HFD-Drug-116high fat diet+AC261066
SA154635C18-pos-HFD-Drug-116bhigh fat diet+AC261067
SA154636anp-pos-HFD-Drug-116bhigh fat diet+AC261067
SA154637anp-neg-HFD-Drug-116bhigh fat diet+AC261067
SA154638C18-neg-HFD-Drug-116bhigh fat diet+AC261067
SA154639C18-neg-HFD-Drug-217high fat diet+AC261068
SA154640anp-neg-HFD-Drug-217high fat diet+AC261068
SA154641C18-pos-HFD-Drug-217high fat diet+AC261068
SA154642anp-pos-HFD-Drug-217high fat diet+AC261068
SA154643C18-neg-HFD-Drug-217bhigh fat diet+AC261069
SA154644C18-pos-HFD-Drug-217bhigh fat diet+AC261069
SA154645anp-neg-HFD-Drug-217bhigh fat diet+AC261069
SA154646anp-pos-HFD-Drug-217bhigh fat diet+AC261069
SA154647C18-pos-HFD-Drug-316high fat diet+AC261070
SA154648anp-pos-HFD-Drug-316high fat diet+AC261070
SA154649anp-neg-HFD-Drug-316high fat diet+AC261070
SA154650C18-neg-HFD-Drug-316high fat diet+AC261070
SA154651C18-pos-HFD-Drug-316bhigh fat diet+AC261071
SA154652C18-neg-HFD-Drug-316bhigh fat diet+AC261071
SA154653anp-pos-HFD-Drug-316bhigh fat diet+AC261071
SA154654anp-neg-HFD-Drug-316bhigh fat diet+AC261071
SA154655C18-pos-HFD-Drug-417high fat diet+AC261072
SA154656anp-neg-HFD-Drug-417high fat diet+AC261072
SA154657anp-pos-HFD-Drug-417high fat diet+AC261072
SA154658C18-neg-HFD-Drug-417high fat diet+AC261072
SA154659anp-neg-HFD-Drug-417bhigh fat diet+AC261073
SA154660C18-pos-HFD-Drug-417bhigh fat diet+AC261073
SA154661C18-neg-HFD-Drug-417bhigh fat diet+AC261073
SA154662anp-pos-HFD-Drug-417bhigh fat diet+AC261073
Showing results 1 to 96 of 96

Collection:

Collection ID:CO001750
Collection Summary:At the termination of the treatments, after fasting overnight mice were sacrificed by cervical dislocation and liver samples were harvested for analysis.
Sample Type:Liver

Treatment:

Treatment ID:TR001770
Treatment Summary:Wild-type (wt) male C57BL/6 mice (6-7 weeks old) were maintained on either a standard laboratory chow (Con) diet with 13 % kcal fat (diet no. 5053, Pico Diet, St. Louis, MO), or a high fat diet (HFD) with 60% kcal from fat (diet no. 58125, Test Diet, Inc., St. Louis, MO) for 4 months. Two months after the start of the HFD, the mice were further split into three groups for 2 months to remain on (i) chow plus drinking water with 0.2 % DMSO; (ii) HFD plus drinking water containing 0.2 % DMSO; or (iii) HFD plus 3 mg AC261066 per 100 ml drinking water with 0.2 % DMSO.

Sample Preparation:

Sampleprep ID:SP001763
Sampleprep Summary:The snap frozen liver samples were incubated with 600 µL of 3 mM monobrombimane (MBB) in CH3OH:H2O (80:20) at -20°C for 2 h, followed by 1 h incubation at 0°C. This initial incubation was followed by tissue disruption using stainless steel beads in a TissueLyser (Qiagen) and an additional 30 min at -20°C. Extracts were centrifuged for 15 min at 13000 rpm to pellet insoluble material and supernatants were transferred to clean tubes. This extraction was repeated two additional times and all three supernatants were dried in a speed-vac (Savant) and stored at −80 °C until analysis.

Combined analysis:

Analysis ID AN002738 AN002739 AN002740 AN002741
Analysis type MS MS MS MS
Chromatography type Normal phase Normal phase Reversed phase Reversed phase
Chromatography system Agilent 1290 Infinity II Agilent 1290 Infinity II Agilent 1290 Infinity II Agilent 1290 Infinity II
Column Cogent Diamond Hydride™ (2.1×150 mm, 3.5 µm) Cogent Diamond Hydride™ (2.1×150 mm, 3.5 µm) Agilent Zorbax RRHD SB-C18 (100 x 2.1mm, 1.8um) Agilent Zorbax RRHD SB-C18 (100 x 2.1mm, 1.8um)
MS Type ESI ESI ESI ESI
MS instrument type QTOF QTOF QTOF QTOF
MS instrument name Agilent 6550 QTOF Agilent 6550 QTOF Agilent 6550 QTOF Agilent 6550 QTOF
Ion Mode POSITIVE NEGATIVE POSITIVE NEGATIVE
Units abundance abundance abundance abundance

Chromatography:

Chromatography ID:CH002024
Chromatography Summary:The mobile phase for ANP separation consisted of 6 mM EDTA and 0.025% acetic acid in isopropanol:H2O (50:50) (solvent A) and 6 mM EDTA and 5mM ammonium acetate in CH3CN: H2O (90:10) (solvent B). Gradient steps were applied as follows: 0–1 min, 99% B; 1–15 min, to 20% B; 15.1–29 min, 0% B; 29.01-35 min, 99% B.
Instrument Name:Agilent 1290 Infinity II
Column Name:Cogent Diamond Hydride™ (2.1×150 mm, 3.5 µm)
Chromatography Type:Normal phase
  
Chromatography ID:CH002025
Chromatography Summary:The mobile phase for RP separation consisted of 1 mM ammonium formate and 0.1% formic acid in H2O (solvent A) and 0.1% formic acid in CH3CN (solvent B). The gradient was as follows: 0–2 min, 1% B; 2– 20 min, to 50% B; 20–25 min, to 85% B; 25-30 min, to 99% B; 30.01-36 min, 1% B.
Instrument Name:Agilent 1290 Infinity II
Column Name:Agilent Zorbax RRHD SB-C18 (100 x 2.1mm, 1.8um)
Chromatography Type:Reversed phase

MS:

MS ID:MS002535
Analysis ID:AN002738
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS Type:ESI
MS Comments:Agilent MassHunter Workstation
Ion Mode:POSITIVE
  
MS ID:MS002536
Analysis ID:AN002739
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS Type:ESI
MS Comments:Agilent MassHunter Workstation
Ion Mode:NEGATIVE
  
MS ID:MS002537
Analysis ID:AN002740
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS Type:ESI
MS Comments:Agilent MassHunter Workstation
Ion Mode:POSITIVE
  
MS ID:MS002538
Analysis ID:AN002741
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS Type:ESI
MS Comments:Agilent MassHunter Workstation
Ion Mode:NEGATIVE
  logo